Product Information
COMBIGAN 0.2%-0.5% EYE DROPS is a brand product labeled by Allergan, Inc., priced at $39.0959 per ML under NDC 00023921110. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Oct 30, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2; 5 mg/mL; mg/mL
Manufacturer
Allergan, Inc.NDC
00023921110
Classification
Brand
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
BRIMONIDINE TARTRATE; TIMOLOL MALEATEApproval Type
New Drug (NDA)
FDA Application
NDA021398FDA Approved
10/30/2007
TE Code
AB
On Market Since
11/14/2007
Pharmacological Classes
Price Statistics
The NADAC for COMBIGAN 0.2%-0.5% EYE DROPS has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 116.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $39.0959 per ML |
|---|---|
| All-time high | $39.2512 (Mar 13, 2024) |
| All-time low | $18.0995 (Nov 28, 2013) |
| 52-week high | $39.2013 |
| 52-week low | $39.0959 |
| Median price | $35.5620 |
| Average price | $32.8085 |
| Largest weekly change | +9.9% (Jan 13, 2016) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
brimonidine tartrate, timolol maleate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
alpha-Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of COMBIGAN 0.2%-0.5% EYE DROPS?
The current National Average Drug Acquisition Cost (NADAC) for COMBIGAN 0.2%-0.5% EYE DROPS, manufactured by Allergan, Inc., is $39.0959 per ML (NDC 00023921110), effective Sep 30, 2026.
How has the price of COMBIGAN 0.2%-0.5% EYE DROPS changed over time?
Over the history we have for it, the NADAC for COMBIGAN 0.2%-0.5% EYE DROPS has risen 116.0%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for COMBIGAN 0.2%-0.5% EYE DROPS?
Since Nov 28, 2013, the NADAC for COMBIGAN 0.2%-0.5% EYE DROPS has ranged from a low of $18.0995 (Nov 28, 2013) to a high of $39.2512 (Mar 13, 2024), with a median of $35.5620 per ML.
Are there cheaper alternatives to COMBIGAN 0.2%-0.5% EYE DROPS?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, COMBIGAN 0.2%-0.5% EYE DROPS, is $39.0913 per ML — about 0% below COMBIGAN 0.2%-0.5% EYE DROPS.
Who manufactures COMBIGAN 0.2%-0.5% EYE DROPS?
COMBIGAN 0.2%-0.5% EYE DROPS (NDC 00023921110) is labeled by Allergan, Inc., and CMS classifies it as a brand product.